BLUE - bluebird bio Operating income before deduction of amortization
bluebird bio, Inc. (BLUE) strives for the complete cure of patients with rare blood pathologies by implementing one-time therapies. Production relies on a global network of CDMO centers to ensure supply chain continuity. However, high logistics costs weaken margins even with FDA protection. The company's absolute operating profit in cash visualizes the real cash flow, where the final mark is .
bluebird bio (BLUE) - metric breakdowns and financial figures
- stock price and consensus target price:
- market capitalization statistics:
- balance sheet equity data:
- debt level and financial liquidity data:
All Debt to Shareholders' Equity Ratio bluebird bio, Inc.|BLUE - Long-Term Debt to Capital|Short-Term Debt to Equity bluebird bio Inc.|BLUE - Company Aggregate Debts|Debts to Net Assets bluebird bio|BLUE - Company Long-Term Debt|Short-Term Debt bluebird bio|Intermediate Coverage Ratio bluebirdbio.com
- earnings and market ratios statistics:
BLUE - Net Profit|Company Profit Forecast bluebird bio, Inc.|BLUE - Price to Earnings Ratio|Price to Future Earnings Ratio bluebirdbio.com|BLUE - PEG Multiple|Enterprise Value to EBITDA Ratio bluebird bio|BLUE - Operating profit before deduction of amortization|Net earnings per share for the last four quarters bluebird bio|BLUE - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months bluebirdbio.com|BLUE - Earnings per share growth in current year|Net earnings per share growth forecast for next year bluebird bio, Inc.
- sales revenue and business income indicators:
Summary company analytics:BLUE bluebird bio, Inc
The stability of bluebird bio, Inc. (BLUE) is determined by its ability to generate cash flow against the backdrop of colossal costs associated with the bespoke production of gene therapies. This metric measures the actual volume of operating cash, allowing for the identification of hidden margin degradation through the base EBITDA level and preventing false conclusions regarding business growth when analyzing historical trends.
Competitors of bluebird bio, Inc. (BLUE)
Tempus - Profit before payment of interest, taxes and amortization|Qiagen N.V. - Operating profit EBITDA|Operating income before deduction of amortization ionispharma.com IONS|Repligen (RGEN) - Profit before payment of interest, taxes and amortization|Avidity Biosciences Inc - Income before deduction of interest, taxes and amortization|CRSP (CRISPR Therapeutics Corp) - Operating profit EBITDA|Operating profit before amortization WGS (GeneDx Corp)|Operating profit before deduction of amortization RARE (Ultragenyx Pharmaceutical)|BEAM (beamtx.com) - Income before deduction of interest, taxes and amortization|Operating profit EBITDA SRPT (Sarepta)|Twist Bioscience Inc - Profit before payment of interest, taxes and amortization|10x Genomics Corp - Operating profit EBITDA|Operating income before deduction of amortization Intellia Corp NTLA|Stoke Therapeutics (STOK) - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization biolifesolutions.com (BLFS)|Operating profit before deduction of amortization WVE|MAZE: Income before deduction of interest, taxes and amortization|Operating profit EBITDA SION|Operating income before deduction of amortization Prime Medicine Bio|Profit before payment of interest, taxes and amortization Taysha Gene Therapies TSHA|QURE: Operating profit before amortization|MeiraGTx - Operating profit EBITDA|REGENXBIO Inc (RGNX) - Operating profit before deduction of amortization|SLDB (Solid Bio) - Operating profit before deduction of amortization|OCGN - Operating income before deduction of amortization|PACB (Pacific Biosciences) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization BNTC|Profit before payment of interest, taxes and amortization Design Therapeutics, Inc. (DSGN)|Profit before payment of interest, taxes and amortization RCKT (Rocket Pharma)|4D Molecular Therapeutics Inc - Operating profit before deduction of amortization|Operating profit EBITDA Lexeo Therapeutics Inc. LXEO|Korro Bio, Inc - Operating profit EBITDA|Profit before interest, taxes and amortization editasmedicine.com|SLN: Operating profit EBITDA|Operating profit before amortization PRQR|Profit before payment of interest, taxes and amortization Codexis Inc|Operating profit before amortization SGMO (Sangamo BioSciences)|Operating profit EBITDA NAUT|Operating profit EBITDA metagenomi.co (MGX)|Operating profit EBITDA DTIL (Precision BioSciences, Inc.)|Generation Bio Co - Profit before payment of interest, taxes and amortization|BOLD - Profit before payment of interest, taxes and amortization|XCUR: Profit before payment of interest, taxes and amortization|IMNN (imunon.com) - Operating profit before deduction of amortization|Phio Pharmaceuticals Corp. (PHIO) - Operating profit EBITDA|MBIO (Mustang Bio Inc) - Operating profit EBITDA|Profit before interest, taxes and amortization TransCode RNAZ|Operating profit EBITDA BNGO|Profit before payment of interest, taxes and amortization APDN (Applied DNA Corp)|Operating profit EBITDA IPA (ImmunoPrecise Antibodies Ltd.)|Operating income before deduction of amortization omegatherapeutics.com (OMGA)|OMIC - Profit before payment of interest, taxes and amortization|Income before deduction of interest, taxes and amortization RGLS (Regulus Therapeutics, Inc.)|SYRS: Operating profit EBITDA|Operating profit before amortization TBIO|Operating profit before deduction of amortization TCON|UBX: Income before deduction of interest, taxes and amortization
